GainersToday.com
GainersToday.com, Tracking Stock Market Picks
Enter Symbol:
 
Medgenics, Inc. (MDGN) [hlAlert]

Rating:
Buy MDGN
up 86.09 %

Medgenics Inc. Common Stock (MDGN) rated Buy with price target $8 by Maxim Group

Posted on: Tuesday,  Aug 23, 2011  9:25 AM ET by Maxim Group

Maxim Group rated Buy Medgenics, Inc. (AMEX: MDGN) on 08/23/2011, when the stock price was $4.10. Since
then, Medgenics, Inc. has gained 86.10% as of 08/27/2015's recent price of $7.63.
If you would have followed this Maxim Group's recommendation on MDGN, you would have gained 86.09% of your investment in 1465 days.

Medgenics, Inc., a commercial-stage biopharmaceutical company, focuses on providing protein therapies. The company develops the Biopump Platform, a proprietary technology, which uses the patient?s own tissue to continuously produce and deliver the patient?s own protein therapy. It is designed to provide protein therapy to treat a range of chronic diseases, including anemia, hepatitis C, hemophilia, multiple sclerosis, arthritis, pediatric growth hormone deficiency, obesity, diabetes, and other chronic diseases or conditions. The company?s product line includes EPODURE, a Biopump producing erythropoietin in Phase I/II clinical trial to treat anemia in patients with chronic kidney disease; INFRADURE, a Biopump producing interferon-alpha in preclinical stage for the treatment of hepatitis-C; and HEMODURE, a Biopump to produce clotting Factor VIII for the treatment of hemophilia. Medgenics, Inc. was founded in 2000 and is based in San Francisco, California.

At Maxim Group, our vision for equity research is to be a client’s first call for value-added research on companies not widely followed by Wall Street. Maxim’s premier niche is emerging-growth companies in a variety of sectors, including healthcare, technology, retail and others. As strong believers in fundamental research, our analysts utilize a “bottom up” approach to making investment recommendations. We combine rigorous financial analysis of specific companies and industries with due diligence that includes frequent consults with suppliers, customers, competitors and senior management. By applying these skills and techniques, we are able to offer our clients differentiated research.
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
8/23/2011 9:25 AM Buy
None
4.10 8.00
as of 12/30/2011
1 Week down  -0.39 %
1 Month down  -23.07 %
3 Months down  -44.44 %
1 YTD down  -39.02 %

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy